Ireland
--:--IST
Recruiting Phase 2/3

Antisecretory Factor Glioblastoma Phase 2

NCT05669820 · tracked via the Priya Life Science Sweden tracker
Phase
Phase 2/3
Started
2024-01-15
Last updated
2026-01-09

Condition(s) studied

Glioblastoma

Investigational drug(s) / intervention(s)

SalovumPlacebo egg yolk powder

Salovum: Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.

Placebo egg yolk powder: Egg yolk powder derived from hen fed with normal feed.

Study summary

This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Pathology verified glioblastoma or astrocytoma grade 4 2. Age 18-75 years 3. Surgical treatment-resection. 4. Scheduled concomitant radiochemotherapy, or only chemotherapy. 5. Informed consent Exclusion Criteria: 1. No informed consent 2. Egg yolk allergy 3. Only surgical biopsy 4. Only radiotherapy

Primary outcome measure(s)

  • Overall survival — up to 12 months from primary surgery
    Survival

Trial sites (1)

FacilityCityRegionStatus
Skåne University Hospital Lund Sweden Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05669820 on ClinicalTrials.gov ↗ ← All trials in Sweden